|Chemical and physical data|
|Molar mass||419.408 g/mol g·mol−1|
|3D model (JSmol)|
DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain. As of June 2014, it is in phase I/phase II clinical trials.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|